Palisade Bio Inc. Stock
Palisade Bio Inc. Stock
With 10 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
Based on the current price of 0.34 € the target price of 6 € shows a potential of 1658.5% for Palisade Bio Inc. which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Palisade Bio Inc. stock. Criterium "Company culture" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.
Pros and Cons of Palisade Bio Inc. in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Palisade Bio Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Palisade Bio Inc. | - | - | - | - | - | - | - |
| Pacira Pharmaceuticals | 2.630% | 3.571% | 6.422% | 25.405% | 7.407% | -28.834% | -54.059% |
| Supernus Pharmaceuticals | -0.490% | 1.463% | 1.961% | 46.479% | -3.256% | 50.725% | 79.310% |
| Collegium Pharmaceutical Inc | 0.000% | 2.632% | -0.637% | 16.418% | -24.638% | 57.576% | 51.456% |
Comments
Palisade Bio (PALI) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $8.00 price target on the stock.
Show more
Ratings data for PALI provided by MarketBeat
Palisade Bio (PALI) had its "buy" rating reaffirmed by HC Wainwright.
Show more
Ratings data for PALI provided by MarketBeat
Palisade Bio (PALI) was upgraded by LADENBURG THALM/SH SH to "strong-buy".
Show more
Ratings data for PALI provided by MarketBeat